MX2018004366A - Aislamiento temprano post-transfeccion de celulas (epic) para la produccion de productos biologicos. - Google Patents

Aislamiento temprano post-transfeccion de celulas (epic) para la produccion de productos biologicos.

Info

Publication number
MX2018004366A
MX2018004366A MX2018004366A MX2018004366A MX2018004366A MX 2018004366 A MX2018004366 A MX 2018004366A MX 2018004366 A MX2018004366 A MX 2018004366A MX 2018004366 A MX2018004366 A MX 2018004366A MX 2018004366 A MX2018004366 A MX 2018004366A
Authority
MX
Mexico
Prior art keywords
cells
epic
sorting
early post
polypeptide
Prior art date
Application number
MX2018004366A
Other languages
English (en)
Inventor
Demaria Christine
R Cairns Victor
Vitko Jason
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2018004366A publication Critical patent/MX2018004366A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70592—CD52

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)

Abstract

En la presente memoria se proporcionan métodos para seleccionar una población de células que expresan un polipéptido blanco. En algunos aspectos, la descripción proporciona métodos para clasificar y seleccionar poblaciones de células hospedantes transfectadas con base a su expresión temprana de un polipéptido seleccionable. En determinadas modalidades, la clasificación se lleva a cabo usando clasificación celular activada por fluorescencia o clasificación celular activada magnéticamente basada en el polipéptido seleccionable. Dichos métodos de selección pueden utilizarse adicionalmente para generar poblaciones clonales de células productoras, p.ej., para fabricación a gran escala de un polipéptido blanco de interés.
MX2018004366A 2015-10-09 2016-10-07 Aislamiento temprano post-transfeccion de celulas (epic) para la produccion de productos biologicos. MX2018004366A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562239515P 2015-10-09 2015-10-09
PCT/US2016/055918 WO2017062724A1 (en) 2015-10-09 2016-10-07 Early post-transfection isolation of cells (epic) for biologics production

Publications (1)

Publication Number Publication Date
MX2018004366A true MX2018004366A (es) 2018-08-01

Family

ID=57211576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004366A MX2018004366A (es) 2015-10-09 2016-10-07 Aislamiento temprano post-transfeccion de celulas (epic) para la produccion de productos biologicos.

Country Status (12)

Country Link
US (4) US10317329B2 (es)
EP (4) EP3359665B1 (es)
CN (3) CN108368504B (es)
AU (3) AU2016335699A1 (es)
CA (2) CA3001364A1 (es)
ES (2) ES3024209T3 (es)
HU (2) HUE071193T2 (es)
IL (4) IL258538B2 (es)
MX (1) MX2018004366A (es)
PL (2) PL3359665T3 (es)
SG (3) SG11201802829YA (es)
WO (2) WO2017062722A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3215191B1 (en) 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
IL258538B2 (en) 2015-10-09 2023-04-01 Genzyme Corp Early isolation after the infection of cells (epic) for the production of biological material
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
CL2016001661A1 (es) * 2016-06-29 2017-03-03 Univ Chile Promotor hibrido de ß-actina (de cricetulus griseus) y citomegalovirus (cmv), con región rica en dinucleótidos, citosina-guanina, vectores, líneas celulares, procedimiento para producir proteínas recombinantes.
EP3831281B1 (en) 2016-08-30 2026-02-25 The Regents of The University of California Devices and systems for biomedical targeting and delivery
ES3021241T3 (en) 2016-10-07 2025-05-26 Genzyme Corp Early post-transfection isolation of cells (epic) for biologics production
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
MX2023005938A (es) 2020-11-19 2023-05-29 Genzyme Corp Sistema de indicadores multiples de expresion atenuada de indicadores por citometria de flujo (flare) y sus metodos de uso.
WO2025186459A1 (en) 2024-03-08 2025-09-12 Sanofi Antigenic epstein barr virus polypeptides

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
CA2063799A1 (en) 1989-07-24 1991-01-25 Frank S. Genbauffe Prevention of internal initiation
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
JP2002513285A (ja) 1997-02-25 2002-05-08 キュービーアイ エンタープライジズ リミテッド 高翻訳効率のｉｒｅｓ配列及びこの配列を含む発現ベクター
US7001733B1 (en) * 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
US20050005310A1 (en) * 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
DE60025829T2 (de) * 1999-07-12 2006-11-02 Genentech, Inc., South San Francisco Expressionsvektoren und anwendungsmethoden
WO2001057212A1 (en) 2000-02-02 2001-08-09 Iconix Pharmaceuticals, Inc. Rapid, parallel identification of cell lines
US6833254B2 (en) 2001-03-01 2004-12-21 The Regents Of The University Of California Method to identify IRES elements
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
DE10143238A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Identifizierung eukaryotischer interner Ribosomen-Eingangsstellen (IRES)-Elemente
CN1668634A (zh) 2002-05-22 2005-09-14 比奥根艾迪克Ma公司 分泌性多肽的检测
US7119187B2 (en) 2002-07-09 2006-10-10 National Health Research Institutes Internal ribosome entry site of the labial gene for protein expression
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
EP1540008A4 (en) * 2002-07-19 2006-04-12 Diversa Corp FLUORESCENT PROTEINS, NUCLEIC ACIDS ENCODING THEM, AND METHODS OF MAKING AND USING SAME
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7344886B2 (en) 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
AU2003300932A1 (en) 2002-12-16 2004-07-29 Wayne State University Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20
PT2332972T (pt) 2003-06-24 2018-04-17 Genzyme Corp Novos promotores de beta-actina e rps21 e suas utilizações
US7776584B2 (en) 2003-08-01 2010-08-17 Genetix Limited Animal cell colony picking apparatus and method
JPWO2005094886A1 (ja) 2004-03-31 2008-02-14 キリンファーマ株式会社 Ｇｐｉアンカー蛋白質アゴニストによる調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物
US7078179B2 (en) 2004-05-04 2006-07-18 Newlink Genetics Corporation Selectable gene marker system based on expression of N-acetyllactosaminide 3-α galactosyltransferase
US20060188964A1 (en) * 2004-07-28 2006-08-24 Filippo Mancia Processing for producing and crystallizing G-protein coupled receptors
BRPI0517380A (pt) 2004-11-08 2008-10-07 Chromagenics Bv molécula de dna, cassete de expressão, célula hospedeira, e, métodos para gerar uma célula hospedeira que expressa um polipeptìdeo de interesse e para produzir um polipeptìdeo de interesse
NZ553700A (en) 2004-11-08 2010-09-30 Chromagenics Bv Selection of host cells expressing protein at high levels using a selectable marker with a non-optimal start codon
CN101068928A (zh) 2004-12-14 2007-11-07 弗·哈夫曼-拉罗切有限公司 RNAi转染子的改良选择方法
CA2648778A1 (en) 2006-04-10 2007-10-18 The Regents Of The University Of California Method for culturing cells on removable pallets for subsequent cell expansion and analysis
ES2388003T3 (es) 2006-09-20 2012-10-05 Genzyme Corporation Un sistema basado en FACS y en la proteína indicadora para un desarrollo de alto rendimiento de proteínas terapéuticas
CA2679393A1 (en) 2007-03-05 2008-09-12 Newsouth Innovations Pty Limited Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents
WO2012001073A2 (en) * 2010-07-01 2012-01-05 Glaxo Group Limited Improved method for selecting high producing cell lines
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
EP2700713B1 (en) * 2012-08-21 2016-07-13 Miltenyi Biotec GmbH Screening and enrichment system for protein expression in eukaryotic cells using a tricistronic expression cassette
EP2970956A1 (en) * 2013-03-11 2016-01-20 Novartis AG Method of screening cell clones
PT3027646T (pt) * 2013-07-31 2018-10-16 Novartis Ag Novos vetores e métodos de seleção de células hospedeiras eucarióticas
IL258538B2 (en) 2015-10-09 2023-04-01 Genzyme Corp Early isolation after the infection of cells (epic) for the production of biological material
ES3021241T3 (en) 2016-10-07 2025-05-26 Genzyme Corp Early post-transfection isolation of cells (epic) for biologics production

Also Published As

Publication number Publication date
IL258537B2 (en) 2024-05-01
CN108368505A (zh) 2018-08-03
IL258538A (en) 2018-05-31
IL309289A (en) 2024-02-01
EP4567425A2 (en) 2025-06-11
US20200018682A1 (en) 2020-01-16
CN108368505B (zh) 2023-02-21
AU2022275507A1 (en) 2023-02-02
CA3001238C (en) 2024-06-25
EP3359666C0 (en) 2025-02-19
IL258537A (en) 2018-05-31
IL258538B (en) 2022-12-01
EP4530350A2 (en) 2025-04-02
WO2017062722A3 (en) 2017-05-26
HK1259493A1 (en) 2019-11-29
US20170121734A1 (en) 2017-05-04
WO2017062722A2 (en) 2017-04-13
SG11201802829YA (en) 2018-05-30
AU2016335699A1 (en) 2018-05-24
EP3359666B1 (en) 2025-02-19
AU2022275507B2 (en) 2025-06-05
IL258537B1 (en) 2024-01-01
EP3359665A2 (en) 2018-08-15
US20230304913A1 (en) 2023-09-28
WO2017062724A1 (en) 2017-04-13
CN116660127A (zh) 2023-08-29
ES3024209T3 (en) 2025-06-04
HUE069884T2 (hu) 2025-04-28
SG10202111233SA (en) 2021-11-29
CN108368504A (zh) 2018-08-03
PL3359665T3 (pl) 2025-04-14
US10317329B2 (en) 2019-06-11
PL3359666T3 (pl) 2025-06-23
EP3359665C0 (en) 2024-11-13
EP3359666A1 (en) 2018-08-15
SG11201802823VA (en) 2018-05-30
ES3008383T3 (en) 2025-03-24
HUE071193T2 (hu) 2025-08-28
US20170227441A1 (en) 2017-08-10
EP3359665B1 (en) 2024-11-13
AU2025226783A1 (en) 2025-09-25
IL258538B2 (en) 2023-04-01
EP4530350A3 (en) 2025-06-25
US12590880B2 (en) 2026-03-31
CA3001238A1 (en) 2017-04-13
CA3001364A1 (en) 2017-04-13
CN108368504B (zh) 2022-07-19
US11635363B2 (en) 2023-04-25
IL297805A (en) 2022-12-01
EP4567425A3 (en) 2025-10-08

Similar Documents

Publication Publication Date Title
EP4567425A3 (en) Early post-transfection isolation of cells (epic) for biologics production
CL2017000528A1 (es) Descubrimiento y producción de proteínas biológicas condicionalmente activas en las mismas células hospederas eucariotas de producción
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
MY189778A (en) Method for producing retinal pigment epithelial cells
BR112018002214A2 (pt) ?métodos para cultivar células e para produzir uma proteína, meios de cultura de células cho e de batelada alimentada e/ou alimentação, e, alimentação de cultura de células cho?
SG10201806890VA (en) Massively parallel single cell analysis
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
EP4219744A3 (en) Methods of preparing nucleic acids for sequencing
SA521421882B1 (ar) نظم، وطرق وجهاز لتمديد مجموعة من الخلايا
EP4446338A3 (en) Cells and method of cell culture
EA201590488A1 (ru) Способы модификации клеток-хозяев
MX2016016902A (es) Metodos para analizar acidos nucleicos de celulas individuales o poblaciones de celulas.
SG10201810830UA (en) Cell culture compositions and methods for polypeptide production
MX2015017110A (es) Integracion dirigida.
MY178364A (en) Method for culturing microalgae of the genus aurantiochytrium in a culture medium without chloride and without sodium for the production of dha
AU2017263716A1 (en) Haematopoietic stem/progenitor cells
MX371025B (es) Células eucariotas novedosas y métodos para la expresión recombinante de un producto de interés.
MX2015012168A (es) Expansión de celulas madre adultas in vitro.
WO2019217493A3 (en) Cell populations and gene expression associated with in vitro beta cell differentiation
MY190347A (en) Production method for insoluble recombinant protein aggregate
MX369109B (es) Selección novedosa de vectores y métodos de selección de células hospederas eucarióticas.
MX2020003508A (es) Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.
MY180352A (en) Recombinant methanotrophic bacterium and a method of production of succinic acid from methane or biogas thereof
MX2021001528A (es) Metodo para la produccion de celulas positivas para cd3.
MX2016000634A (es) Metodo optimizado para la ruptura de paredes celulares de chlorella por medio de homogeneizacion a muy alta presion.